Filing
3rd Quarter - Report
Lobbying activity
4
Patent Thickets, Patent Settlements, Interchangeability of biosimilars, Q1Q2 transparency, PBM Reform, Inflation Reduction Act, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
Incentivizing domestic manufacturing of essential medicines.